Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Feihai Ma

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Medicinal Research Reviews|June 5, 2026
Selective Targeting of STAT6: Recent Advances and Future PerspectivesHua Liu, Feihai Ma, Zexu Wang, et al.
Journal of Medicinal Chemistry|February 13, 2025
Rational Design of a Potent, Selective, and Metabolically Stable CDK9 Inhibitor to Counteract Osimertinib Resistance through Mcl-1 Suppression and Enhanced BRD4 Co-TargetingTizhi Wu, Jiali Huang, Xiankang Zhang, et al.
Journal of Medicinal Chemistry|September 11, 2025
Discovery of Tricyclic Derivative as Novel and Potent Respiratory Syncytial Virus Fusion Glycoprotein Inhibitor with an Improved Pharmacokinetic ProfileLi'ao Zhang, Bao Xue, Mingkang Cao, et al.
European Journal of Medicinal Chemistry|September 6, 2023
Discovery of novel flavonoid-based CDK9 degraders for prostate cancer treatment via a PROTAC strategyTizhi Wu, Zhiming Zhang, Guangyue Gong, et al.
Journal of Medicinal Chemistry|October 23, 2023
Discovery of Selective and Potent Macrocyclic CDK9 Inhibitors for the Treatment of Osimertinib-Resistant Non-Small-Cell Lung CancerTizhi Wu, Bin Yu, Yifan Xu, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Medicinal Research Reviews|June 5, 2026
Selective Targeting of STAT6: Recent Advances and Future PerspectivesHua Liu, Feihai Ma, Zexu Wang, et al.
Journal of Medicinal Chemistry|February 13, 2025
Rational Design of a Potent, Selective, and Metabolically Stable CDK9 Inhibitor to Counteract Osimertinib Resistance through Mcl-1 Suppression and Enhanced BRD4 Co-TargetingTizhi Wu, Jiali Huang, Xiankang Zhang, et al.
Journal of Medicinal Chemistry|September 11, 2025
Discovery of Tricyclic Derivative as Novel and Potent Respiratory Syncytial Virus Fusion Glycoprotein Inhibitor with an Improved Pharmacokinetic ProfileLi'ao Zhang, Bao Xue, Mingkang Cao, et al.
European Journal of Medicinal Chemistry|September 6, 2023
Discovery of novel flavonoid-based CDK9 degraders for prostate cancer treatment via a PROTAC strategyTizhi Wu, Zhiming Zhang, Guangyue Gong, et al.
Journal of Medicinal Chemistry|October 23, 2023
Discovery of Selective and Potent Macrocyclic CDK9 Inhibitors for the Treatment of Osimertinib-Resistant Non-Small-Cell Lung CancerTizhi Wu, Bin Yu, Yifan Xu, et al.
Pageof 1